XTX Topco Ltd Invests $490,000 in Keros Therapeutics, Inc. (NASDAQ:KROS)

Key Points

• XTX Topco Ltd acquired a new position in Keros Therapeutics, purchasing 48,121 shares valued at approximately $490,000 during the first quarter.
• Analysts have lowered price targets for Keros Therapeutics, with Bank of America cutting their target from $32.00 to $18.00, and Scotiabank reducing theirs from $41.00 to $26.00.
• Keros Therapeutics reported a significant revenue increase of 49002.7% compared to the same quarter last year, although it faced an EPS loss of ($0.76), which was better than analysts' consensus estimates.

XTX Topco Ltd bought a new position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 48,121 shares of the company's stock, valued at approximately $490,000. XTX Topco Ltd owned about 0.12% of Keros Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of KROS. KLP Kapitalforvaltning AS purchased a new stake in shares of Keros Therapeutics in the fourth quarter worth $90,000. Vanguard Group Inc. raised its stake in shares of Keros Therapeutics by 5.4% in the fourth quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company's stock worth $30,981,000 after purchasing an additional 100,691 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Keros Therapeutics by 585.9% in the fourth quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company's stock worth $3,379,000 after purchasing an additional 182,314 shares during the last quarter. Norges Bank purchased a new stake in shares of Keros Therapeutics during the fourth quarter valued at $1,027,000. Finally, Geode Capital Management LLC boosted its position in shares of Keros Therapeutics by 5.5% during the fourth quarter. Geode Capital Management LLC now owns 765,436 shares of the company's stock valued at $12,120,000 after buying an additional 39,815 shares during the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

KROS has been the topic of several recent analyst reports. Wedbush reaffirmed a "neutral" rating and set a $15.00 price objective on shares of Keros Therapeutics in a research report on Friday, May 30th. Scotiabank dropped their price objective on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research report on Monday, May 12th. HC Wainwright dropped their price objective on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a research report on Friday. Finally, Bank of America cut Keros Therapeutics from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $32.00 to $18.00 in a research report on Tuesday, June 10th. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Keros Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $30.00.

Keros Therapeutics Stock Up 2.5%

NASDAQ:KROS traded up $0.33 on Tuesday, hitting $13.68. The stock had a trading volume of 70,714 shares, compared to its average volume of 998,335. The business's 50-day simple moving average is $14.00 and its two-hundred day simple moving average is $12.81. The stock has a market cap of $555.76 million, a price-to-earnings ratio of 44.14, a price-to-earnings-growth ratio of 1.80 and a beta of 1.33. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.38. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%. The firm's quarterly revenue was up 49002.7% on a year-over-year basis. During the same quarter last year, the company earned ($1.25) EPS. As a group, equities research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.